 |
|
|
| |
Limited sustained response and lack of HBsAg decline
after stopping long-term nucleos(t)ide analogue therapy
in HBeAg negative patients with chronic hepatitis B:
Results of the prospective, randomized, open-label phase IV
STOP study
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Kin Seng LiemŽ1,2, Scott Fung1, David K. Wong1, Colina Yim1, Seham Noureldin1, Feng Fei Huang1, Hemant Shah1, Jordan J. Feld1,3, Bettina E. Hansen1,2,4, Harry L.A. Janssen1
1 Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, Canada.
2 Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
3 McLaughlin-Rotman Centre for Global Health, Toronto, Canada.
4 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
|
| |
|
|
|
|
|
